Recommendations for biomarker data collection in clinical trials by longevity biotechnology companies.

Chiara M S Herzog, Jesse R Poganik, Nicola Boekstein, Kristen Fortney, James G Peyer, Jim Mellon, Risa Starr, Nir Barzilai, Mahdi Moqri

Department of Twin Research and Genetic Epidemiology, School of Life Course and Population Sciences, Faculty of Medicine and Life Sciences, King's College London, London, UK.Department of Twin Research and Genetic Epidemiology, School of Life Course and Population Sciences, Faculty of Medicine and Life Sciences, King's College London, London, UK. · pubmed

Paper

Abstract

Biomarkers of aging have the potential to transform geroscience clinical trials because of their broad applications in stratifying participants, prioritizing interventions, and monitoring responses to geroprotectors. As longevity biotechnology companies (LBCs) continue to plan and launch innovative clinical trials, standard practices in collecting data and applying biomarkers of aging will allow the field to support parallel and ongoing validation and benchmarking efforts for aging biomarkers. Moreover, defining best practices will ensure future reuse of valuable clinical data through pre-competitive alignment on shared tools. Here, we propose recommendations for such collections. We believe that wide adoption of these recommendations will allow LBCs to produce and leverage the highest quality data from their clinical trials, while also benefiting the geroscience field more broadly with minimal additional effort.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper proposes recommendations for biomarker data collection in clinical trials conducted by longevity biotechnology companies. This research is relevant as it addresses the standardization of biomarker usage in clinical trials aimed at understanding and potentially mitigating the aging process.

Author of this paper? Send a correction.